Literature DB >> 12466283

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.

Cédric Blanpain1, Benjamin J Doranz, Antoine Bondue, Cédric Govaerts, Anne De Leener, Gilbert Vassart, Robert W Doms, Amanda Proudfoot, Marc Parmentier.   

Abstract

CCR5 is a functional receptor for various inflammatory CC-chemokines, including macrophage inflammatory protein (MIP)-1alpha and RANTES (regulated on activation normal T cell expressed and secreted), and is the main coreceptor of human immunodeficiency viruses. The second extracellular loop and amino-terminal domain of CCR5 are critical for chemokine binding, whereas the transmembrane helix bundle is involved in receptor activation. Chemokine domains and residues important for CCR5 binding and/or activation have also been identified. However, the precise way by which chemokines interact with and activate CCR5 is presently unknown. In this study, we have compared the binding and functional properties of chemokine variants onto wild-type CCR5 and CCR5 point mutants. Several mutations in CCR5 extracellular domains (E172A, R168A, K191A, and D276A) strongly affected MIP-1alpha binding but had little effect on RANTES binding. However, a MIP/RANTES chimera, containing the MIP-1alpha N terminus and the RANTES core, bound to these mutants with an affinity similar to that of RANTES. Several CCR5 mutants affecting transmembrane helices 2 and 3 (L104F, L104F/F109H/F112Y, F85L/L104F) reduced the potency of MIP-1alpha by 10-100 fold with little effect on activation by RANTES. However, the MIP/RANTES chimera activated these mutants with a potency similar to that of MIP-1alpha. In contrast, LD78beta, a natural MIP-1alpha variant, which, like RANTES, contains a proline at position 2, activated these mutants as well as RANTES. Altogether, these results suggest that the core domains of MIP-1alpha and RANTES bind distinct residues in CCR5 extracellular domains, whereas the N terminus of chemokines mediates receptor activation by interacting with the transmembrane helix bundle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466283     DOI: 10.1074/jbc.M205684200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

Review 3.  The attraction of chemokines as a target for specific anti-inflammatory therapy.

Authors:  James E Pease; Timothy J Williams
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

Review 5.  Rational design of novel HIV-1 entry inhibitors by RANTES engineering.

Authors:  Luca Vangelista; Massimiliano Secchi; Paolo Lusso
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

6.  Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists.

Authors:  Ting Wang; Yong Duan
Journal:  J Mol Graph Model       Date:  2007-12-17       Impact factor: 2.518

7.  Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Authors:  Jun Jin; Philippe Colin; Isabelle Staropoli; Evelyne Lima-Fernandes; Cécile Ferret; Arzu Demir; Sophie Rogée; Oliver Hartley; Clotilde Randriamampita; Mark G H Scott; Stefano Marullo; Nathalie Sauvonnet; Fernando Arenzana-Seisdedos; Bernard Lagane; Anne Brelot
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

8.  Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Authors:  D J Scholten; M Canals; M Wijtmans; S de Munnik; P Nguyen; D Verzijl; I J P de Esch; H F Vischer; M J Smit; R Leurs
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 9.  Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.

Authors:  C L Salanga; T M Handel
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 10.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.